AbbVie Yönetim

Yönetim kriter kontrolleri 2/4

AbbVie CEO'su Robert Michael, Jul2024 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 32.53M olup, şirket hissesi ve opsiyonları dahil olmak üzere 5.2% maaş ve 94.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.01% ine doğrudan sahiptir ve bu hisseler ARS 53.69B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 9.7 yıldır.

Anahtar bilgiler

Robert Michael

İcra Kurulu Başkanı

US$32.5m

Toplam tazminat

CEO maaş yüzdesi	5.23%
CEO görev süresi	1.8yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	9.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Robert Michael'un ücretlendirmesi AbbVie'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	US$4b
Dec 31 2025	US$33m	US$2m	US$4b
Sep 30 2025	n/a	n/a	US$2b
Jun 30 2025	n/a	n/a	US$4b
Mar 31 2025	n/a	n/a	US$4b
Dec 31 2024	US$18m	US$2m	US$4b
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$5b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$14m	US$1m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$10m	US$1m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$12m	US$1m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$13m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$9m	US$907k	US$8b

Tazminat ve Piyasa: Robert 'nin toplam tazminatı ($USD 32.53M ), AR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.96M ).

Tazminat ve Kazançlar: Robert şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Robert Michael (55 yo)

1.8yrs

Görev süresi

US$32,530,984

Tazminat

Mr. Robert A. Michael, C.P.A., served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as it...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Michael	CEO & Chairman of the Board	1.8yrs	US$32.53m	0.010% ARS 53.7b
Scott Reents	Executive VP & CFO	3.9yrs	US$12.35m	0.0022% ARS 11.6b
Azita Saleki-Gerhardt	Executive VP & COO	1.8yrs	US$10.79m	0.012% ARS 61.4b
Roopal Thakkar	Executive VP of Research & Development and Chief Scientific Officer	1.8yrs	US$9.91m	0.0031% ARS 16.6b
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.44m	0.0048% ARS 25.4b
Linda Ray	Senior VP & Chief Information Officer	less than a year	Veri yok	Veri yok
Elizabeth Shea	Senior Vice President of Investor Relations	no data	Veri yok	Veri yok
Perry Siatis	Executive VP	3.6yrs	Veri yok	0.00026% ARS 1.4b
Demetris Crum	Executive VP & Chief Human Resources Officer	1.3yrs	Veri yok	0.00045% ARS 2.4b
Wulff-Erik von Borcke	Senior VP & President of Oncology	2.6yrs	Veri yok	Veri yok
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	3.3yrs	Veri yok	0.0042% ARS 22.3b
Tracie Haas	Senior Vice President of Corporate Affairs	2.3yrs	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: ABBV 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Michael	CEO & Chairman of the Board	1.8yrs	US$32.53m	0.010% ARS 53.7b
Roxanne Austin	Lead Independent Director	13.3yrs	US$432.88k	0.00065% ARS 3.4b
Thomas Freyman	Independent Director	6yrs	US$397.88k	0.0071% ARS 37.6b
Edward Rapp	Independent Director	13.3yrs	US$383.44k	0.0010% ARS 5.4b
William H. Burnside	Independent Director	13.3yrs	US$382.88k	Veri yok
Frederick Waddell	Independent Director	13.3yrs	US$402.88k	0.00011% ARS 583.6m
Melody Meyer	Independent Director	9yrs	US$407.88k	0% ARS 0
Brett Hart	Independent Director	10.3yrs	US$397.88k	Veri yok
Rebecca Roberts	Independent Director	8yrs	US$372.88k	Veri yok
Robert Alpern	Independent Director	13.3yrs	US$498.49k	0.000010% ARS 53.1m
Susan Quaggin	Independent Director	2.6yrs	US$359.51k	0% ARS 0
Jennifer Davis	Independent Director	2.6yrs	US$372.88k	0% ARS 0

9.7yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ABBV 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/22 17:19
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

AbbVie Inc. 51 Bu analistlerden 29, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Emily Field	Barclays
Luisa Hector	Berenberg

AbbVie Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

AbbVie Inc., Annual General Meeting, May 08, 2026

AbbVie Inc., Annual General Meeting, May 09, 2025

AbbVie Inc. Announces Board Changes, Effective July 1, 2025

Recent updates

AbbVie Inc. Presents New Long-Term Data For Skyrizi And Rinvoq In Inflammatory Bowel Diseases

Abbvie Announces Skyrizi (Risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis

AbbVie Announces Superiority of Rinvoq Versus Humira for Primary Endpoint in Head-To-Head Study in Rheumatoid Arthritis Patients

Abbvie Provides Update on Trenibotulinumtoxine Biologics License Application in the U.S

AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (Elahere) in Platinum-Sensitive Ovarian Cancer

AbbVie Inc. to Report Q1, 2026 Results on Apr 29, 2026

AbbVie Announces to Present New Research Across its Dermatology Portfolio at 2026 American Academy of Dermatology Annual Meeting

AbbVie Inc., Annual General Meeting, May 08, 2026

AbbVie Announces Positive Topline Results from Phase 3 Affirm Study Evaluating SKYRIZI®? (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

U.S. Food and Drug Administration Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

AbbVie Inc. Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVO) in Adults and Adolescents With Vitiligo

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

AbbVie Denies Media Reports of Talks to Buy Revolution Medicines

AbbVie Inc. to Report Q4, 2025 Results on Feb 04, 2026

Abbvie Receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus

AbbVie to Feature New Data At ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

AbbVie Corporation Announces Two Positive Updates for Canadians Living with Ulcerative Colitis

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Abbvie Announces New 6-Month 45Mg Luprolide Acetate for Extended-Release Injectable Suspension

AbbVie Inc. Announces Launch of Second Winds

AbbVie Inc. Announces Intangible Asset Impairment for the Third Quarter Ended September 30, 2025

AbbVie Inc. Declares Increase in Quarterly Cash Dividend, Payable on February 17, 2026

AbbVie Corporation Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers

Abbvie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (Rinvoq®?) in Adult and Adolescents with Vitiligo

Abbvie Announces Positive Topline Results from the Phase 3B/4 Head-To-Head Study

AbbVie Announces U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ®? (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

AbbVie Announces Positive Topline Results from Phase 2 Elite Trial Evaluating OnabotulinumtoxinA (BotoX®?) for the Treatment of Upper Limb Essential Tremor

AbbVie Inc. to Report Q3, 2025 Results on Oct 31, 2025

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab Sunirine (PVEK) - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment Options

AbbVie Announces UK Pricing Strategy for ELAHERE®? (Mirvetuximab Soravtansine-gynx)

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

AbbVie's VRAYLAR®? (Cariprazine) Now Publicly Reimbursed in Alberta

Abbvie Inc. Declares Quarterly Dividend, Payable on November 14, 2025

AbbVie Announces Updated Results from Phase 2 EPCORE®? NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients with Relapsed/Refractory (R) Diffuse Large B-Cell Lymphoma (DLBCL)

Abbvie Announces Positive Topline Results from Second Phase 3 Up-Aa Trial Evaluating Upadacitinib (Rinvoq®?) for Alopecia Areata

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Capstan Therapeutics, Inc.

AbbVie Reportedly in Talks to Acquire Gilgamesh in $1 Billion Deal

Abbvie Announces Positive Topline Results from Phase 3 Up-Aa Trial Evaluating Upadacitinib for Alopecia Areata

Abbvie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia

AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada

AbbVie Inc. to Report Q2, 2025 Results on Jul 31, 2025

AbbVie Inc Declares Quarterly Cash Dividend, Payable August 15, 2025

Genentech and AbbVie Provide Update on Phase III Verona Study

U.S. FDA Approves Expanded Indication for Abbvie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

Abbvie Features New Data Across Difficult-To-Treat Solid Tumors and Blood Cancers At Asco 2025

The Gross Law Firm Files Lawsuit Against Cerevel Therapeutics Holdings, Inc

Abbvie Announces U.S. FDA Approves Emrelis for Adults with Previously Treated Advanced Non-Small Cell Lung Cancer (Nsclc) with High C-Met Protein Overexpression

AbbVie Inc. Announces U.S. Food and Drug Administration Approval for Giant Cell Arteritis

AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

AbbVie Inc. Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

AbbVie Inc. to Report Q1, 2025 Results on Apr 25, 2025

AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

AbbVie Announces Final Analysis of the Confirmatory Phase 3 MIRASOL Trial Evaluating the Efficacy and Safety of ELAHERE®?

AbbVie Inc., Annual General Meeting, May 09, 2025

AbbVie Announces SKYRIZI (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®?) for the Treatment of Adults with Giant Cell Arteritis

AbbVie Inc. Announces Board Changes, Effective July 1, 2025

Abbvie Announces the U.S. Food and Drug Administration Approves Emblaveo™

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Nimble Therapeutics, Inc.

Abbvie and Regenxbio Inc. Announce Updates on the Abbv-Rgx-314 Clinical Program

AbbVie Inc. to Report Q4, 2024 Results on Jan 31, 2025

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million.

AbbVie Inc. (NYSE:ABBV) complete the acquisition of Aliada Therapeutics, Inc. from Johnson & Johnson Innovation - JJDC, Inc., RA Capital Management, L.P., RA Ventures, OrbiMed Advisors LLC and Sanofi Ventures.

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

AbbVie Inc. Announces Updated Results from the Phase 1b/2 EPCORE® NHL-2 Trial Evaluating Fixed-Duration Investigational Epcoritamab

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing